‼️
#MODERNA UNDER SHORT ATTACK: 17.6% SHORT INTEREST AND AN EXPLOSIVE SHORT SQUEEZE SETUP ‼️
📊 Q1 2025 Results:
• 💰 Revenue: $108M (−35% YoY)
• 📉 Adj. EPS: –$2.52 (improved from –$3.07 YoY)
📅 2025 Guidance:
• 📎 Revenue: $1.5–2.5B (–53% to –22% YoY)
• 🧪 Excludes potential sales from new product approvals
🔬 Key Products & Pipeline:
• 💉 Spikevax (COVID vaccine): sales –50% YoY to $84M
• 📦 Distributor stockpiles from 2024 likely dragged down demand
• 🌍 Market now seasonal (annual fall shots), but demand fading in EMs strong competition from
$PFE and
$NVAX
• ⚠️ 2026 forecast: sales may fall below $1B
• 🦠 mRESVIA (RSV vaccine): only $2M in sales
• 📆 FDA decision for high-risk adults (18–59) expected June 12
• 📈 Bull case: $200M in 2025 revenue
• 🤝
$MRK partnership: ~20% of Q1 revenue from collaboration (funding mRNA-4157 trials)
🎯 The Real Bet: mRNA-4157
• 🧬 Key oncology pipeline candidate
• 🏦 $5.98B in cash (as of Mar 31, 2025) — fully funds trial completion
• ⏳ Results expected late 2025–2026
• 🧨 Make-or-break asset — either massive upside or collapse
🐻 SHORT INTEREST SPIKING:
• 🚨 April short interest: 17.6% (up from 14.6% in March)
• ⚖️ Fundamentals still weak, but…
• 🔥 Setup for a violent short squeeze is forming
Bullish Catalysts:
• 💼 Strong partnership with
$MRK
• 🚫 No shareholder dilution
• 🔒 Tight float
• ⚡ Any positive clinical/regulatory news = explosive upside
🧾 Short Interest Across Healthcare:
🔝 Most Shorted:
1.
$MRNA – 17.58%
2.
$DVA – 6.62%
3.
$RMD – 6.47%
4.
$CRL – 5.45%
5.
$HSIC – 5.09%
🔻 Least Shorted:
1.
$BSX – 1.07%
2.
$UNH – 0.98%
3.
$MDT – 0.87%
4.
$LLY – 0.87%
5.
$JNJ – 0.82%
#ShortSqueeze #HighShortInterest #ShortCovering #SqueezeSetup #BiotechSqueeze #OptionsGamma #MarketSqueeze #ShortAttack #ExplosiveMove #ShortTrap #MRNASqueeze